Cost considerations in the medical management of glaucoma in the US: estimated yearly costs and cost effectiveness of bimatoprost compared with other medications

PharmacoEconomics
Lawrence D Goldberg, John Walt

Abstract

The aim of this study was to evaluate the cost effectiveness of glaucoma treatment with bimatoprost compared with other intraocular pressure (IOP)-lowering medications in adult patients with chronic glaucoma or ocular hypertension (IOP of between 22 mm Hg and 34 mm Hg), from a US healthcare payers' perspective. Estimated yearly costs and cost per treatment success for 0.03% bimatoprost once daily (Lumigan) were compared with 0.5% timolol twice daily (generic), 0.005% latanoprost once daily (Xalatan) and the fixed combination of 0.5% timolol and 2.0% dorzolamide twice daily (Cosopt). The model was based on year 2003 medical resource costs (physician visits and drug acquisition costs) and treatment success rates from published clinical trials. The clinical measure utilised was the percentage of patients achieving target IOPs. A higher percentage of patients achieved target IOPs with bimatoprost than with each of the other medications. At most target pressures, the cost per treatment success for patients starting treatment on bimatoprost was less than that for patients started on other drugs. This was true despite that, when looking at costs alone, the estimated yearly costs for bimatoprost (averaged over both patient success and ...Continue Reading

References

Jan 12, 1984·The New England Journal of Medicine·P Doubilet, H L Abrams
Jan 1, 1993·Ophthalmologica. Journal international d'ophtalmologie. International journal of ophthalmology. Zeitschrift für Augenheilkunde·M ShirakashiK Nanba
Apr 18, 2000·Ophthalmology·K SinghD Minckler
Sep 27, 2001·Advances in Therapy·S GandolfiUNKNOWN Bimatoprost Study Group 3
Oct 9, 2002·Archives of Ophthalmology·Anders HeijlUNKNOWN Early Manifest Glaucoma Trial Group
Jan 22, 2003·Value in Health : the Journal of the International Society for Pharmacoeconomics and Outcomes Research·Milton C WeinsteinUNKNOWN ISPOR Task Force on Good Research Practices--Modeling Studies
Jun 18, 2003·Clinical Therapeutics·Gregory ReardonEssy Mozaffari
Jan 15, 2005·Journal of Ocular Pharmacology and Therapeutics : the Official Journal of the Association for Ocular Pharmacology and Therapeutics·Douglas G DayWilliam C Stewart
Feb 5, 2005·Ophthalmology·Anastasios G P KonstasWilliam C Stewart
Mar 4, 2005·Current Opinion in Ophthalmology·Gail F Schwartz
Apr 22, 2005·Value in Health : the Journal of the International Society for Pharmacoeconomics and Outcomes Research·Andrew Briggs
Aug 25, 2005·Journal of Ocular Pharmacology and Therapeutics : the Official Journal of the Association for Ocular Pharmacology and Therapeutics·Richard Fiscella, William C Stewart

❮ Previous
Next ❯

Citations

Jan 26, 2008·Canadian Journal of Ophthalmology. Journal Canadien D'ophtalmologie·Jean LachaineShaila Mensinkai
Nov 22, 2007·Survey of Ophthalmology·Jan D HirschShira L Robbins
Oct 31, 2009·Expert Opinion on Pharmacotherapy·A Jayaprakash PatilDeepak P Edward
May 20, 2006·Current Medical Research and Opinion·David Covert, Alan L Robin
Sep 14, 2006·Current Medical Research and Opinion·Jordana K SchmierAlan L Robin
Jan 1, 2008·Journal of Medical Economics·Daniela KolevaLivio Garattini
Nov 29, 2016·Medicine·Gabriel Lazcano-GomezJesús Jimenez-Román
Feb 24, 2009·Current Medical Research and Opinion·Jordana K SchmierAlan L Robin
Mar 1, 2011·Expert Opinion on Emerging Drugs·Anne J Lee, Ivan Goldberg
Aug 28, 2020·International Ophthalmology·Maryam YadgariFatemeh Vafaei

❮ Previous
Next ❯

Related Concepts

Related Feeds

Antihypertensive Agents: Mechanisms of Action

Antihypertensive drugs are used to treat hypertension (high blood pressure) which aims to prevent the complications of high blood pressure, such as stroke and myocardial infarction. Discover the latest research on antihypertensive drugs and their mechanism of action here.